Fractyl Health (GUTS) REMAIN-1 Trial Concealment Case

Attorneys review the case details to decide whether to proceed with a class action.

S.D. New York

Court

1:26-cv-07167

Case number

01/13/2025

Class period Start

01/29/2026

Class period End

10/20/2026

Lead Plaintiff motion deadline

$GUTS investors filed a claim against Fractyl Health, Inc. for touting overstated efficacy data for its Revita weight-maintenance device while concealing operational problems at a clinical trial site that were skewing the results.
Fractyl's stock fell 68% in a single day after six-month data from its REMAIN-1 Midpoint Cohort study showed far weaker efficacy than the company's earlier, more promising readouts, with the CEO acknowledging a study site had contributed materially skewed results.
$GUTS investors can join this case to be notified about potential recovery.
Case Details:

Fractyl Health is a metabolic therapeutics company developing Revita, an outpatient procedural therapy intended to help patients maintain weight loss after discontinuing GLP-1 drugs like tirzepatide. 

Throughout the Class Period, Fractyl repeatedly touted positive interim data from two study cohorts within its REMAIN-1 program: the open-label REVEAL-1 Cohort and the randomized REMAIN-1 Midpoint Cohort. 

Company statements characterized data readouts as "groundbreaking," "clinically and statistically significant," and showing "clear evidence of Revita activity," while CEO Harith Rajagopalan repeatedly emphasized the Midpoint Cohort's importance as an early, reliable readout for the larger, 315-patient Pivotal Cohort. 

In August and September 2025, on days coinciding with these positive data releases, Fractyl conducted two public stock offerings, raising roughly $77 million in combined proceeds.

What the company did not disclose was that operational issues at one of the Midpoint Cohort's six clinical sites, including a less robust diet and lifestyle counseling program, were compromising the integrity of the cohort's efficacy results. 

On January 29, 2026, Fractyl announced six-month data from the Midpoint Cohort showing Revita-treated patients regained 4.5% of body weight compared to 7.5% in the sham arm, a far more modest result than earlier readouts had suggested. 

On the same day's earnings call, Rajagopalan acknowledged that "central statistical monitoring" had flagged one site with "a high degree of variability in weight regain" that was "contributing materially" to the disappointing results. Fractyl's stock fell $1.245, or 68.03%, to close at $0.585 on January 29, 2026. 

The next day, after Morgan Stanley downgraded the stock and cut its price target from $8.00 to $2.00, citing the disappointing data and the site-specific issue, shares fell a further 21.37% to close at $0.46.

Based on these events, $GUTS investors filed a claim against Fractyl, alleging the company:
Overstated Revita's efficacy in maintaining weight loss after GLP-1 discontinuation
Concealed operational issues at a REMAIN-1 Midpoint Cohort clinical site that compromised the integrity of its efficacy results
Misrepresented Revita's clinical, regulatory, and commercial prospects while raising tens of millions of dollars in stock offerings tied to the inflated data
Investors argue Fractyl misled the market about the reliability of its pivotal clinical trial data, causing losses when the six-month Midpoint Cohort results and the disclosed site-specific issues revealed the true, previously concealed state of Revita's trial results.

Case Type

US Securities Class Action

Case Status

Attorney Investigation

Alleged Offence

Misleading Statements,

Failure to Disclose

Suspected Party

Directors,

Management

Security Type

Stocks

Trade Direction

Long

Shock Event Date

01/29/2026

Filing date

08/21/2026

Lead Plaintiff Deadline

10/20/2026